Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
March 29, 2023
Javier speaks with Natasha Loder from The Economist and John Burn-Murdoch from The Financial Times about keeping pace with the demand for information during the Covid-19 pandemic, confronting the flood of misinformation and disinformation, and lessons learned on reporting during health emergencies.
Blog Post
March 15, 2023
The COVID-19 pandemic resulted in the deepest global recession since World War II. Countries across the world implemented substantial mitigation measures in response to the economic shock of the pandemic, with the size of the economic stimulus measures averaging about 5.6 percent of GDP. Social pro...
Blog Post
March 07, 2023
The EU and its member states are collectively the world’s largest aid donor, with an annual budget of over $70 billion in 2021. When it comes to global health, however, it has historically punched below its weight. In part, this is due to an internal coordination problem; health is a shared competen...
Blog Post
March 03, 2023
The COVID-19 pandemic led to a deep global recession as the virus rapidly spread and governments restricted movements. The economic shock was compounded by widespread uncertainty among businesses and concerns about the risks of increasing financial sector distress limiting access to credit.
Blog Post
January 13, 2023
The new year has hardly begun, but fears of a looming recession persist. Pandemic-era increases in health spending are unlikely to continue in low- and middle-income countries. Growing fiscal pressures—such as high debt, increasing interest rates, and declining foreign aid and revenues—bode ominous...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
Blog Post
December 02, 2022
An important debate is taking place in Europe right now on how to fund new antimicrobials. For months it has been speculated that the European Union may move towards implementing transferable exclusivity vouchers (TEVs). In response, 14 Member States wrote to the European Commission outlining why th...
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...